Treatment of Posaconazole-Induced Peripheral Neuropathy With Methylprednisolone and Magnesium Infusions: A Case Report
Sadia Hussaina, Susan Nissenb, Steven M. Hollandc, Paola Sandronid, Michail S. Lionakise✉
- aCritical Care Medicine Department, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland
- bDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Health Systems, Faribault, Minnesota
- cImmunopathogenesis Section, Laboratory of Clinical Immunology & Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland
- dDepartment of Neurology, Mayo Clinic, Rochester, Minnesota
- eFungal Pathogenesis Section, LCIM, NIAID, NIH, Bethesda, Maryland
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
The tolerability of long-term posaconazole use remains poorly defined. We present a patient who developed peripheral neuropathy following long-term exposure to the tablet formulation of posaconazole, which was treated with methylprednisolone and magnesium infusions. The potential role of methylprednisolone and magnesium infusions in managing this potentially irreversible triazole-associated complication requires further study.
TL;DRA patient who developed peripheral neuropathy following long-term exposure to the tablet formulation of posaconazole is presented, which was treated with methylprednisolone and magnesium infusions. (Semantic Scholar)